Synergistic antioxidant and anti-inflammatory action of N-acetylcysteine in portal hypertensive gastropathy in rats

Francielli Licks1, Renata Minuzzo Hartmann2, Elizângela Schemitt2, Josieli Raskopf Colares3, Camila Marques4, Henrique Fillmann5, Norma Possa Marroni1,2

1Program in Biological Sciences: Physiology, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, RS, Brazil; 2Program in Medicine: Medical Sciences, UFRGS, Porto Alegre, RS, Brazil; 3Program in BioHealth, Universidade Luterana do Brasil (ULBRA), Canoas, RS, Brazil; 4Health Science Education Program, Faculdades Pequeno Príncipe, Curitiba, PR, Brazil; 5School of Medicine, Pontifícia Universidade Católica do Rio Grande do Sul (PUCRS), Porto Alegre, RS, Brazil

Abstract

Background and Aim: Portal hypertension (PH) is a syndrome associated with cirrhosis and characterized by a progressive increase in portal pressure, with consequent compensatory vascular dilation. Gastric vascular changes associated with oxidative and nitrosative stress characterize the clinical presentation of portal hypertensive gastropathy (PHG). In addition, the inflammatory process is considered an aggravating factor for severity by contributing to gastric tissue injury. The aim of this study was to investigate the synergistic anti-inflammatory and antioxidant action of N-acetylcysteine (NAC) in the stomach of rats with PH.

Materials and Methods: Eighteen Wistar male rats were used in this experimental protocol and were divided into three groups with six in each group: sham-operated (SO), partial portal vein ligation (PPVL), and PPVL + NAC. Treatment with NAC at a dose of 10 mg/kg (i.p.) was initiated on day 8 after surgery and continued for 7 days. We evaluated the expression of iNOS, NQO-1, HSP-90, and SOD by Western blot, as well as nuclear factor-kappa B (NF-xB) and tumor necrosis factor (TNF)-α staining by immunohistochemistry, in the rat stomach.

Results: The PPVL group exhibited increased expression of HSP-90, iNOS, SOD, and NQO-1 when compared with controls. NAC reduced the expression of all studied proteins. Similarly, NF-xB and TNF-α staining was increased in PPVL animals versus controls and reduced in PPVL + NAC versus PPVL animals, respectively.

Conclusion: These results suggest the effectiveness of NAC as a dual anti-inflammatory and antioxidant in animals with experimental PHG induced by partial ligation of the portal vein.

Keywords: Inflammation; N-acetylcysteine; oxidative stress; portal hypertension.

Introduction

The portal system is responsible for leading blood from the intra-abdominal portion of the gastrointestinal tract, pancreas, spleen, and gallbladder to the liver sinusoids via the terminal branches of the portal vein.[1] Pre-hepatic abnormalities (such as splenic vein thrombosis), intrahepatic abnormalities (such as cirrhosis), and post-hepatic conditions (such as Budd-Chiari syndrome) may all influence blood pressure within the portal system. The only shared characteristic of the aforementioned examples is the emergence of an anatomical barrier to blood flow. This obstacle triggers a compensatory mechanism to reduce blood pressure, promoting the development of hyperdynamic collateral circulation. This condition, characterized by a progressive increase of pressure in the portal system, is called portal hypertension (PH).[2]

The resulting bypass of blood flow from the site of obstruction directly into the systemic circulation triggers serious complications, such as ascites, hepatic encephalopathy, and gastrointestinal bleeding, with the latter accounting for the high mortality rate of 50% among patients with PH.[3]

Microcirculatory alterations in the gastric mucosa as a result of the characteristic vasodilation of HP were described by McCormack et al. in 1985.[4] Several different terms have been used to describe these changes, such as inflammatory gastritis, gastric mucosal vasculopathy, portal hypertensive mucosa, and portal hypertensive gastropathy (PHG).[5]

PHG is characterized by vasodilation secondary to obstruction of gastric blood flow, and nitric oxide (NO) is the main mediator in this vascular activation pathway.[6] NO is an endothelium-derived relaxing factor produced from L-arginine and molecular oxygen, in a process catalyzed by enzymes in the nitric oxide synthase (NOS) family. The three major NOS isoforms, neuronal NOS (nNOS and NOS1), inducible NOS (iNOS and NOS2), and endothelial NOS (eNOS and NOS3), are described in the literature, with well-established roles. NOS2 can be expressed in various cell types, and it plays an important role in inflammatory diseases and septic shock. NOS3 is expressed in endothelial cells and acts on endothelial smooth muscle relaxation.[7] All three isoforms have been associated with PH; however, the most influential isoforms in this syndrome are NOS2 and NOS3.[8] NOS3 is closely related to several factors and proteins that have positive and negative impacts on its production. Proteins that positively influence the production of this enzyme include the positive regulator molecular chaperone heat shock protein 90 (HSP90).[9]
Shear stress and vascular endothelial growth factor (VEGF) also act on the pathway that stimulates the production of NOS, and both have been studied previously in investigations conducted by our research group.\(^{[10,11]}\)

NOS, produces a relatively high level of NO. This isomerase is expressed in response to stimulation from lipopolysaccharides or inflammatory cytokines, and its expression is modulated by transcriptional mechanisms. Nuclear factor-kappa B (NF-kB) is the primary mediator for the induction of iNOS, which, in turn, is activated mainly by tumor necrosis factor (TNF)-α and oxidative stress.\(^{[3]}\)

In PH, overproduction of NO via NOS, and NOS, determines its reaction with the superoxide anion radical (\(\text{O}_2^\cdot\)), leading to the formation of peroxynitrite (ONOO⁻). This, in turn, is a highly reactive species that can contribute to cellular damage, thus aggravating the overall clinical picture.\(^{[12]}\)

The inflammation characteristic of PH affects gastric regeneration and defense, thus increasing the risk of bleeding.\(^{[13]}\) Currently, one hypothetical treatment strategy involves the direct reduction of proinflammatory chemokines and cytokines, which contribute to the progression of PH.\(^{[14]}\)

Thus, treatment with both antioxidant and anti-inflammatory action would represent a promising candidate for minimizing the consequences of PHG. Previous work published by our research group has demonstrated the antioxidant properties of N-acetylcysteine (NAC), a molecule used extensively in clinical practice, in an experimental model of PH.\(^{[15]}\) The aim of this study was to evaluate the synergistic action of NAC as an antioxidant and anti-inflammatory in PHG.

### Materials and Methods

#### Ethics

All procedures were carried out in accordance with current Brazilian legislation for the practice of scientific research using animals (Law 11.794 of October 8, 2008, 2013 Brazilian Guidelines for the Care and Use of Animals for Scientific and Educational Purposes, and 2013 CONCEA Guidelines for the Practice of Euthanasia) and followed the recommendations of the Principles of Care for Laboratory Animals formulated by the National Society for Medical Research and the Guide for the Care and Use of Laboratory Animals published by the National Institutes of Health.

#### Animal Groups and Experimental Protocols

The animals used in this study were obtained through vivarium, in accordance with institutional specifications. Throughout the experiment, animals were kept in plastic bin-type cages (47 × 34 × 18 cm) lined with wood shavings, under a 12-h light/dark cycle, at a temperature of 22 ± 4°C. They had access to water ad libitum and were fed commercially available rodent chow (Purina®–Nutripal, Porto Alegre, RS, Brazil), approximately 16 g/day.

On the first day of the experiment, the Wistar male rats were randomly divided into three groups (n = 18 animals): sham-operated (SO) (n = 6), partial portal vein ligation (PPVL) (n = 6), and PPVL + NAC (n = 6). All animals were weighed (±250 g) and anesthetized with ketamine (100 mg/kg i.p.) and xylazine (10 mg/kg i.p.). Once a proper plane of anesthesia had been achieved, a midline laparotomy was performed, and the bowel was gently retracted with a gauze pad soaked in saline. In group SO, only manipulation of the portal vein was performed, whereas in the other groups, the vein was ligated for experimental induction of PH. Briefly, the portal vein was isolated with 3-0 silk thread, partially blocked using a 20G needle placed in front of the vessel, and tied off. After ligation, the needle was removed, thus leaving the vein partially obstructed. Bowel loops were gently replaced into the abdomen, 10 mL of saline solution infused the abdominal cavity, and the muscle closed with running sutures. The experimental model used in this study was first described by Sikuler et al.\(^{[15]}\) in 1985 and induces pre-hepatic PH.

After the surgical procedures, animals were kept in individual cages. Metamizole was administered for postoperative analgesia, with the first dose given via intramuscular injection (200 mg/kg) and subsequent doses given orally (500 mg/kg every 8 h for 72 h).

Seven days were allowed to elapse for the establishment of PHG before starting treatment. NAC (Sigma Chemical Co., St. Louis, MO, USA; CAS registry number 616-91-1) was administered intraperitoneally at a dose of 10 mg/kg, in agreement with previous studies.\(^{[11,12]}\) The drug was dissolved in 0.6 mL of saline (0.9% NaCl), and the same volume was administered to groups that received vehicle only (SO and PPVL). Treatment was continued for 7 days, thus completing the full 15-day experimental period.

### Western Blot

Western blot analysis was performed using cytosolic extract prepared from stomach homogenates. The protein concentration of each sample was measured by the Bradford method. Then, lysate proteins were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to polyvinylidene fluoride membranes. The membranes were blocked by submerging in Tris–buffered saline room temperature with secondary goat anti-mouse IgG-HRP sc-2005, mouse monoclonal antibody [SOD (sc-8637), Santa Cruz Biotechnology, Santa Cruz, CA, USA]; goat monoclonal antibody [NOS (sc-7721), Santa Cruz Biotechnology, Santa Cruz, CA, USA]; mouse monoclonal antibody [HSP90 (sc-101494), Santa Cruz Biotechnology, Santa Cruz, CA, USA]; goat monoclonal antibody [NQO1 (sc-16464), Santa Cruz Biotechnology, Santa Cruz, CA, USA]; goat monoclonal antibody [SOD (sc-8637), Santa Cruz Biotechnology, Santa Cruz, CA, USA]; at 1:200 dilution with TTBS in 5% nonfat dry milk; and anti-β-actin (42-kDA) antibody (Sigma Aldrich, St. Louis, MO, USA) at 1:1000 dilution with TTBS in 5% nonfat dry milk. After overnight incubation, the membranes were washed with TTBS and incubated for 1 h at room temperature with secondary goat anti-mouse IgG-HRP sc-2005, donkey anti-goat antibody (sc-2020, Santa Cruz Biotechnology, Santa Cruz, CA, USA, 1:4000). Protein detection was performed via chemiluminescence using a commercial ECL kit (Amersham Pharmacia Biotech, Little Chalfont, England). The density of the specific bands was quantified with imaging densitometry software (Scion Image, Maryland, MA, USA).\(^{[16]}\)
The expression of NF-κB and TNF-α in stomach tissue was analyzed using immunohistochemical techniques. Buffer at 100°C was used for antigen retrieval, and endogenous peroxidase activity was blocked by incubation in absolute methanol. Slides were then incubated with rabbit polyclonal antibody (NF-κB [sc-9072], 1:200, Santa Cruz Biotechnology, Santa Cruz, CA, USA) and goat monoclonal antibody (TNF-α [sc-1351], 1:200, Santa Cruz Biotechnology, Santa Cruz, CA, USA) overnight at 4°C, followed by washing with buffer and incubation with secondary goat anti-rabbit IgG-HRP (sc-2004) for 30 min at room temperature. The slides were analyzed under a microscope equipped with a digital camera, and images were captured using Image-Plus software (Media Cybernetics, Bethesda, MD, USA). Quantification of staining for both markers was performed by digital image analysis in Adobe Photoshop® CS3 Extended 10.0, by counting the number of pixels stained. The level of expression was determined by multiplying the average density of the image by the percentage of positively stained areas (those colored brown).

Statistical Analysis
Analysis of Variance was used to evaluate the quantitative data, followed by the Student–Newman–Keuls test for the analysis of multiple comparisons. The significance level was set at 5% (p<0.05). All data are presented as mean ± SE. The GraphPad InStat version 3.0 program for Windows was used.

Results
Western Blotting Analysis
Analysis of HSP90 protein expression revealed a significant increase in the PPVL group compared with controls (p<0.01). NAC effectively reduced these values in the LPVP + NAC group (p<0.01) (Fig. 1).

When evaluating the expression of iNOS, a decrease was observed in the LPVP + NAC group (p<0.05) and a significant increase in the LPVP group (p<0.01) (Fig. 2).

NAC was able to substantially reduce SOD values in the treated group, up to control levels (p<0.05). In the LPVP group, SOD was overexpressed when compared with the SO group (p<0.05) (Fig. 3).

In the analysis of NQO1 protein expression, NAC significantly reduced the values in the LPVP + NAC group when compared with the LPVP group.
group (p<0.05), which had a significantly increased expression when compared with the control group (p<0.05) (Fig. 4).

**Immunohistochemistry**

Animals in the PPVL group showed a significant increase in positive staining for NF-κB as compared with controls (p<0.01). NAC was effective in reducing this immunoreactivity in the PPVL + NAC group (p<0.01) (Fig. 5).

The same pattern of expression was observed in the analysis of TNF-α. In the PPVL group, there was intense staining as compared with the SO group (p<0.01); in the PPVL + NAC group, this immunoreactivity was reduced (p<0.01) (Fig. 6).

**Discussion**

PH, often described as a complication of chronic liver disease, is characterized by increased blood pressure in the portal system, splanchnic vasodilation, and subsequent formation of portosystemic collaterals.[18] The stomach is one of the main sites affected by this marked increase in vascular diameter; accordingly, gastropathy is one of the most frequent complications of PH. In practice, gastric lesions are typically located at the fundus and superior portion of the body of the stomach[19] and are characterized by a mosaic-like pattern, with or without cherry-red spots.[20] Still, the release of inflammatory mediators and consequent gastric inflammation appears to contribute to the development and worsening of gastropathy of PH.[21]

The involvement of NO in the development of hyperdynamic collateral circulation was originally proposed in 1991 by Vallance and Moncada. [22] This hypothesis has since been confirmed by several studies that demonstrated NO as the main mediator of vascular abnormalities in PH. [9,23] In previous investigations, our research group found increased expression of two NOS isoforms predominantly involved in the activation of NO synthesis (eNOS and iNOS), using an animal model of PH.[10,24] An increase in eNOS expression is already detectable in the early stages of PH induced by carbon tetrachloride (CCl4),[25] and eNOS appears to be the major enzymatic pathway for NO synthesis.[26] Agonists in the eNOS activation pathway include shear stress, VEGF, and HSP90, among others. Furthermore, inflammatory cytokines such as TNF-α appear to influence NO production by eNOS.[27]
Another modulator of NO upregulation is VEGF, which is activated by increased portal pressure. Through its angiogenic activity, VEGF ultimately contributes to increased blood flow in the splanchnic territory and to local vasodilation. In the present study, animals subjected to the same experimental model had increased expression of HSP90 when compared with controls (Fig. 1), which demonstrates the influence of this chaperone in the eNOS activation pathway and confirms previous results published by Ai et al., in which HSP90 was overexpressed in the endothelium of mesenteric vessels in PPVL animals.

HSP90 in PH exerts an agonist effect on NO production and vasodilation via eNOS. NAC was able to reduce the expression of HSP90 in the model tested herein. Therefore, the chosen treatment appears to fully modulate the studied pathway, reducing the levels not only of VEGF but also of HSP90, thereby contributing to a reduction in vasodilation mediated by eNOS (Fig. 1).

In PPVL-induced gastric lesions, NOS is highly upregulated. The inducible form of NOS is activated during disease progression and may even be regulated by NF-κB. Stimulation of iNOS expression occurs along with the activation of the innate and adaptive immune systems, infiltration by polymorphonuclear leukocytes, and recruitment of lymphocytes. The latter produce large amounts of NO and cytokines that modulate the inflammatory process, such as TNF-α. Our results showed higher expression of iNOS in PPVL animals (Fig. 2). This enzyme is overexpressed in the gastric mucosa of animals with PHG. Our results suggest that gastric inflammation is clearly established in this experimental model, which is consistent with the literature.

NAC has modulatory activity at different stages of the inflammatory and phagocytic process, stimulating immune functions and reducing levels of proinflammatory cytokines. Furthermore, it inhibits the production of NO via iNOS. In this study, animals treated with NAC exhibited reductions in iNOS expression in the stomach and, therefore, an attenuation of gastric damage caused by these processes, contributing to the integrity of gastric tissue and mitigating the injuries caused by this experimental model.

From the findings of this study, we conclude that the experimental model of PPVL successfully induces PH with subsequent inflammation and oxidative stress in the gastric mucosa. Furthermore, we suggest that a synergistic antioxidant and anti-inflammatory effect of NAC was able to attenuate the damage caused by these processes, contributing to the integrity of gastric tissue and mitigating the injuries caused by this experimental model.

**Ethics Committee Approval:** Institutional Committee for the Care and Use of Animals, Hospital de Clínicas de Porto Alegre, Animal Experimentation Unit (date: 01.13.2014, number: 2014-0012).

**Peer-review:** Externally peer-reviewed.

**Author Contributions:** Concept – FL, RMH, ES, JRC, CM, HF, NPM; Design – FL, RMH, ES, JRC, CM, HF, NPM; Supervision – HF, NPM; Fundings – HF, NPM; Materials – FL, RMH, ES, JRC; Data Collection and/or Processing – FL, RMH, ES, JRC; Analysis and/or Interpretation – FL, RMH, ES, JRC, CM, HF, NPM; Literature Search – FL, RMH, ES, JRC; Writing – FL, RMH, ES, JRC, CM, HF, NPM; Critical Reviews – FL, RMH, ES, JRC, CM, HF, NPM.
Synergistic action of NAC in portal hypertensi

Financial Disclosure: Supported by Fundo de Incentivo à Pesquisa e Eventos (FIPE/HCPA).

References

1. Martineilli ALC. Portal hypertension. Medicina. 2000;37(3):253-261. [Português]
2. Bari K, Garcia-Tsao G. Treatment of portal hypertension. World J Gastroenterol 2012;18(11):1166-1175.
3. Goossens N, Nakagawa S, Hoshida Y. Molecular prognostic prediction in liver cirrhosis. World J Gastroenterol 2015;21(36):10262-10273.
4. McCormack TT, Sims J, Eyer-Brook I, Kennedy H, Goepel J, Johnson AG, et al. Gastric lesions in portal hypertension: inflammatory gastritis or congestive gastrothrapy? Gut 1985;26(11):1226-1232.
5. Mekaroonkamol P, Cohen R, Chawla S. Portal hypertensive enteropathy. World J Hepatol 2015;7(2):127-138.
6. Gracia-Sanco J, Maeso-Díaz R, Bosch J. Pathophysiology and a rational basis of therapy. Dig Dis 2013;33(4):508-514.
7. Förstermann U, Sessa WC. Nitric oxide synthases: regulation and function. Eur Heart J 2012;33(7):829-837, 837a-e837d.
8. Hu LS, George J, Wang JH. Current concepts on the role of nitric oxide in portal hypertension. World J Gastroenterol 2013;19(11):1707-1717.
9. Martell M, Coll M, Ezkurdi N, Raurell I, Genescà J. Physiopathology of splanchic vasodilation in portal hypertension. World J Hepatol 2010;2(6):208-220.
10. Marques C, Licks F, Zattoni I, Borges B, de Souza LE, Marroni CA, Marroni NP. Antioxidant properties of glutamine and its role in VEGF-Akt pathways in portal hypertension gastropathy. World J Gastroenterol 2013;19(28):4464-4474.
11. Licks F, Hartmann MM, Marques C, Schmitt E, Colares JR, Soares Mdo C, et al. N-acetylcysteine modulates angiogenesis and vasodilation in stomach such as DNA damage in blood of portal hypertensive rats. World J Gastroenterol 2015;21(43):12351-12360.
12. Vercellino R, Tieppo J, Dias AS, Marroni CA, Garcia E, Meurer L, et al. N-acetylcysteine effects on genotoxic and oxidative stress parameters in cirrhotic rats with hepatopulmonary syndrome. Basic Clin Pharmacol Toxicol 2008;102(4):370-376.
13. Urrunaga NH, Rockey DC. Portal hypertensive gastropathy and colopathy. Clin Liver Dis 2014;18(2):389-406.
14. Garbuzenko DV. Contemporary concepts of the medical therapy of portal hypertension under liver cirrhosis. World J Gastroenterol 2015;21(20):6117-6126.
15. Sikuler E, Kravetz D, Grossmann RJ. Evolution of portal hypertension and mechanisms involved in its maintenance in a rat model. Am J Physiol 1985;248(6 Pt 1):G618-G625.
16. Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A 1979;76(9):4350-4354.
17. Gaffey MJ, Mills SE, Swanson PE, Zarbo RJ, Shah AR, Wick MR. Immunoreactivity for BER-EP4 in adenocarcinomas, adenomatoid tumors, and malignant mesotheliomas. Am J Surg Pathol 1992;16(6):593-599.
18. Sauerbruch T, Trebicka J. Future therapy of portal hypertension in liver cirrhosis - a guess. F1000Prime Rep 2014;6:95.
19. Ripoll C, Garcia-Tsao G. Management of gastropathy and gastric vascular ectasia in portal hypertension. Clin Liver Dis 2010;14(2):281-295.
20. Cumillas R, Rockey DC. Portal hypertensive gastropathy: A review. Liver Int 2010;30(8):1094-1102.
21. Aller MA, Arías JL, Cruz A, Arías J. Inflammation: A way to understanding the evolution of portal hypertension. Theor Biol Med Model. 2007;4:44.
22. Vallance P, Moncada S. Hyperdynamic circulation in cirrhosis: a role for nitric oxide? Lancet 1991;337(8744):776-778.
23. Bolognesi M, Di Pascoli M, Verardo A, Gatta A. Splanchnic vasodilation and hyperdynamic circulatory syndrome in cirrhosis. World J Gastroenterol 2014;20(10):2555-2563.
24. Moreira AJ, Fraga C, Alonso M, Collado PS, Zettler C, Marroni C, et al. Quercetin prevents oxidative stress and NF-kappaB activation in gastric mucosa of portal hypertensive rats. Biochem Pharmacol 2004;68(10):1939-1946.
25. Bolognesi M, Sacchetto D, Di Pascoli M, Angelí P, Quarta S, Sticca A, et al. Haeme oxidase mediates hyporeactivity to phenylephrine in the mesenteric vessels of cirrhotic rats with ascites. Gut 2005;54(11):1630-1636.
26. Cahill PA, Redmond EM, Hodges R, Zhang S, Sitzmann JV. Increased endothelial nitric oxide synthase activity in the hyperemic vessels of portal hypertensive rats. J Hepatol 1996;25(3):370-378.
27. Ikawir Y. Endothelial dysfunction in the regulation of cirrhosis and portal hypertension. Liver Int 2012;32(2):199-213.
28. Ai J, Yang Z, Qiu FZ, Zhu T. Heat shock protein 90 is responsible for hyperdynamic circulation in portal hypertensive rats. World J Gastroenterol. 2003(11):2544-2547.
29. Moleda L, Jurzik L, Froh M, Güeßle E, Hellerbrand C, Straub RH, et al. Role of HSP-90 for increased nNOS-mediated vasodilation in mesenteric arteries in portal hypertension. World J Gastroenterol 2010;16(15):1837-1844.
30. de Andrade RQ, Moura FA, dos Santos JM, de Araújo OR, de Farias Santos JC, Goulart MO. Oxidative stress and inflammation in hepatic diseases: Therapeutic possibilities of N-acetylcysteine. Int J Mol Sci 2015;16(12):30269-30308.
31. Zhuang RX, Wang FG, Zhou HP, Shi TT, Liu SR. [The protective effect of N-acetylcysteine magnesium against liver cirrhosis with portal hypertension in rat]. Zhonghua Shi Yan He Lin Chuan Bing Du Xue Za Zhi 2012;26(5):366-369. [Chinese]
32. Lawrence T. The nuclear factor NF-kappaB pathway in inflammation. Cold Spring Harb Perspect Biol 2009;1(6):a001651.
33. Baldwin AS Jr. The NF-kappaB and I kappa B proteins: new discoveries and insights. Annu Rev Immunol 1996;14:649-683.
34. Glezer I, Marcourakis T, Avellar MCW, Gorenstein C, Scavone C. The role of the transcription factor NF-kB in the molecular mechanisms of action of psychoactive drugs. Rev Bras Psiquiatr. 2000;22(1):26-30. [Portuguese]
35. Samuni Y, Goldstein S, Dean OM, Berk M. The chemistry and biological activities of N-acetylcysteine. Biochim Biophys Acta 2008;1788(2):211-220.
36. Arranz L, Fernández C, Rodríguez A, Ribera JM, De la Fuente M. The glutathione precursor N-acetylcysteine improves immune function in postmenopausal women. Free Radic Biol Med 2008;45(9):1252-1262.
37. Oka S, Kamata H, Kamata K, Yagisawa H, Hirata H. N-acetylcysteine suppresses TNF-induced NF-kappaB activation through inhibition of IkappaB kinases. FEBS Lett 2000;472:196-202.
38. Mikkelsen RB, Wardman P. Biological chemistry of reactive oxygen and nitrogen and radiation-induced signal transduction mechanisms. Oncogene 2003;22(37):5734-5754.
39. Licks F, Marqués C, Zettler C, Martínis MI, Marroni CA, Marroni NP. Antioxidant effect of N-acetylcysteine on prehepatic portal hypertensive gastrophathy in rats. Ann Hepatol 2014;13(3):370-377.
40. Moreira AJ, Rodrigues G, Bona S, Cerski CT, Marroni CA, Mauriz JL, et al. Oxidative stress and cell damage in a model of precancerous lesions and advanced hepatocellular carcinoma in rats. Toxicol Rep 2014;2(3):332-340.
41. Mari M, Colell A, Morales A, von Montfort C, García-Ruiz C, Fernández-Checa JC. Redox control of liver function in health and disease. Antioxid Redox Signal 2012;16(11):1295-1311.
42. Venugopal R, Jaiswal AK. Nrf1 and Nrf2 positively and c-Fos and Fra1 negatively regulate the human antioxidant response element-mediated expression of NADPH:quinone oxidoreductase1 gene. Proc Natl Acad Sci U S A. 1996;93(25):14960-14965.